The IPO Buzz: Braveheart Bio Prices Upsized IPO at $18 – Above Range – & Stock Pops 68 Percent
Braveheart Bio (BRVE) of San Francisco upsized its IPO at pricing and priced the deal at $18.00 - $1.00 above the top of its range – to raise $382.5 million on Wednesday night, Aug. 5, 2026. The Phase 3 biotech’s deal was increased at pricing to 21.25 million shares – up 2.5 million shares – from 18.75 million shares in the prospectus. The price range was $15.00 to $17.00. At p..
Read more August 6, 2026IPO Calendar
| Company | Symbol proposed | Shares (Millions) | Est. $ Volume | Expected to Trade | SCOOP Rating | Rating Change |
|---|---|---|---|---|---|---|
| Braveheart Bio | BRVE | 21.3 | $ 382.5 mil | 8/6/2026 Priced | S/O | S/O |
| BlossomHill Therapeutics | BLSM | 9.4 | $ 150.0 mil | 8/7/2026 Friday | S/O | S/O |
| Latigo Biotherapeutics | LTGO | 19.2 | $ 345.6 mil | 8/7/2026 Friday | S/O | S/O |
Last 100 IPOs - August 6, 2026
| Number of IPOs priced : | 100 |
| Number Up: | 59 |
| Number Down: | 38 |
| Number Unchanged: | 3 |
| Percentage Change From Issue Price: | 8.04% |
| Percentage Change for The Nasdaq Composite | 35.22% |
2026 IPO Scorecard - August 6, 2026
| Number of IPOs priced (Excluding 136 units) : | 107 |
| Number Up: | 61 |
| Number Down: | 43 |
| Number Unchanged: | 3 |
| Total Return From Issue Price: | 7.29% |
| The Nasdaq Composite Index YTD % Change | 35.22% |